Tonix Pharmaceuticals announces two publications of data on TNX-1500

Tonix Pharmaceuticals announced the on-line publication of two papers1,2 in the American Journal of Transplantation by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, MGH, in collaboration with Tonix Pharmaceuticals. The data involve studies of Tonix’s TNX-1500 product candidate in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand, which is also known as CD154, T-BAM or 5c8 antigen. The publications include data demonstrating that TNX-1500 showed activity in preventing organ rejection and was well tolerated in non-human primates. "There remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejections with an acceptable level of tolerability. TNX-1500 is a third generation anti-CD40L mAb that has been designed by protein engineering to decrease FcgammaRII binding and to reduce the potential for thrombosis. The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. Tonix expects to start a first-in-human Phase 1 study in the second quarter of 2023 of TNX-1500 for prophylaxis of organ rejection in adult patients receiving a kidney transplant."